My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

692.58 -10.68 (-1.52%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 9, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗

November 13, 2025

These top growth stocks have plenty of room left to run.

Via The Motley Fool

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

Via Benzinga

Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack

November 10, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with...

Via StockStory

Topics Artificial Intelligence

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

November 10, 2025

Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For October 28, 2025 ↗

October 28, 2025

Via Benzinga

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗

November 08, 2025

Merck said Saturday its new pill — a possible rival to Regeneron and Amgen — lowered high cholesterol by almost 60%.

Via Investor's Business Daily

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

November 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

November 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

November 06, 2025

Via Benzinga

Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗

November 04, 2025

Via Benzinga

The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality

November 04, 2025

In the dynamic world of finance, where fortunes are made and lost in the blink of an eye, a chilling sentiment has begun to grip investors: the idea that stocks can, indeed, go down. This isn't merely...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

November 04, 2025

Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit...

Via StockStory

Topics Earnings

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗

November 03, 2025

Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.

Via Benzinga

Regeneron Announces Investor Conference Presentations

November 03, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Beaten-Down Stocks That Could Be About to Rally ↗

November 03, 2025

It would be best to get in before the rest of the market pounces on these opportunities.

Via The Motley Fool

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

October 31, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage

October 29, 2025

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per...

Via StockStory

Regeneron (REGN) Q3 2025 Earnings Call Transcript ↗

October 28, 2025

Regeneron (REGN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Uncover the latest developments among S&P500 stocks in today's session. ↗

October 28, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

October 28, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗

October 28, 2025

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump-Xi meeting, and major tech earnings.

Via Benzinga

Topics Economy

Why Are Regeneron (REGN) Shares Soaring Today

October 28, 2025

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit.

Via StockStory

Topics Artificial Intelligence

These S&P500 stocks are gapping in today's session ↗

October 28, 2025

Let's have a look at the S&P500 gap up and gap down stocks in today's session.

Via Chartmill

Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

October 28, 2025

Via Benzinga

These S&P500 stocks that are showing activity before the opening bell on Tuesday. ↗

October 28, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Via Chartmill

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗

October 28, 2025

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales.

Via Benzinga

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts ↗

October 28, 2025

Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit.

Via Investor's Business Daily

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates ↗

October 28, 2025

Regeneron (REGN) Q3 2025 earnings beat estimates with $11.83 EPS on $3.75B revenue. Strong performance driven by Dupixent and Libtayo sales growth.

Via Chartmill

Topics Earnings

Regeneron (NASDAQ:REGN) Surprises With Strong Q3

October 28, 2025

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was...

Via StockStory

Regeneron Reports Third Quarter 2025 Financial and Operating Results

October 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.